Lasa Supergeneri

Which are the latest news on Lasa Supergeneri?

Why is Lasa Supergenerics Ltd falling/rising?

As of 05-Sep, Lasa Supergenerics Ltd's stock price is at 6.75, reflecting a 2.17% decline and a significant year-to-date drop of 27.96%. The stock is underperforming its sector and trading below its moving averages, indicating a bearish trend and reduced investor participation.

As of 05-Sep, Lasa Supergenerics Ltd's stock price is falling, currently at 6.75, which reflects a decrease of 0.15 or 2.17%. The stock has underperformed its sector by 1% today and has been on a consecutive decline for the last two days, resulting in a total drop of 2.44% during this period. Over the past week, the stock has decreased by 2.60%, while its performance over the last month shows a decline of 3.71%. Year-to-date, the stock has fallen significantly by 27.96%, compared to a 10.21% decline in the Sensex.<BR><BR>Additionally, Lasa Supergenerics Ltd is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. There is also a notable decrease in investor participation, with the delivery volume on September 3 falling by 20.15% against the 5-day average. This combination of underperformance, declining moving averages, and reduced trading activity contributes to the stock's current downward trajectory.

Who are in the management team of Lasa Supergeneri?

The management team of Lasa Supergeneri includes Omkar P Herlekar (Chairman & Managing Director), Shivanand Hedge (Whole-time Director), and five Independent Directors: Hardesh Tolani, Ajay Sukhwani, Ekta Gurnasinghani, Manali Bhagtani, along with Mitti M Jain (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Lasa Supergeneri includes the following individuals:<BR><BR>1. **Omkar P Herlekar** - Chairman & Managing Director<BR>2. **Shivanand Hedge** - Whole-time Director<BR>3. **Hardesh Tolani** - Independent Director<BR>4. **Ajay Sukhwani** - Independent Director<BR>5. **Ekta Gurnasinghani** - Independent Director<BR>6. **Mitti M Jain** - Company Secretary & Compliance Officer<BR>7. **Manali Bhagtani** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Lasa Supergeneri do?

Lasa Supergenerics Ltd manufactures and trades chemicals, APIs, and pharmaceuticals, operating as a micro-cap company with a market cap of INR 34 Cr. As of June 2026, it reported net sales of 1 Cr and a net loss of 4 Cr.

Overview: <BR>Lasa Supergenerics Ltd is engaged in the manufacturing, trading, and processing of chemicals, APIs, pharmaceuticals, and drugs, operating within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Lasa Supergenerics Limited was incorporated on March 11, 2016. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -4 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 34 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.02 <BR>Return on Equity: -18.64% <BR>Price to Book: 0.41<BR><BR>Contact Details: <BR>Address: C-105 MIDC, Mahad Raigad Maharashtra : 402301 <BR>Tel: 91-2145-232101/232202 <BR>Email: cs@lasalabs.com <BR>Website: http://www.lasalabs.com

Who are the peers of the Lasa Supergeneri?

Lasa Supergeneri's peers include ANG Lifesciences, Vista Pharma, Chandra Bhagat, Sandu Pharma, Medi Caps, Guj. Terce Labs, Cian Healthcare, Welcure Drugs, and JFL Life. Cian Healthcare leads in 1-year returns at 252.28%, while Lasa Supergeneri has a return of -15.84%.

Peers: The peers of Lasa Supergeneri are ANG Lifesciences, Vista Pharma., Chandra Bhagat, Sandu Pharma., Medi Caps, Guj. Terce Labs., Cian Healthcare, Welcure Drugs, and JFL Life.<BR><BR>Quality Snapshot: Below Average management risk is observed at ANG Lifesciences, Vista Pharma., Chandra Bhagat, Medi Caps, Guj. Terce Labs., Cian Healthcare, and the rest. Average management risk is found at Sandu Pharma. and Welcure Drugs, while JFL Life has Excellent management risk. Below Average growth is noted for ANG Lifesciences, Vista Pharma., Chandra Bhagat, Cian Healthcare, and the rest, while Average growth is seen at Guj. Terce Labs., and Sandu Pharma. has Below Average growth. Lasa Supergeneri has Average capital structure, while Good capital structure is observed at Sandu Pharma., Medi Caps, Welcure Drugs, and the rest.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Vista Pharma. has the lowest at -36.98%. Lasa Supergeneri's 1-year return of -15.84% is better than Vista Pharma.'s but worse than Cian Healthcare's. Additionally, the six-month returns for Welcure Drugs, Lasa Supergeneri, and Medi Caps are negative.

How big is Lasa Supergeneri?

As of 31st August, Lasa Supergenerics Ltd has a market capitalization of 34.00 Cr and reported net sales of 6.36 Cr with a loss of 16.54 Cr over the latest four quarters. Shareholder's funds were 83.71 Cr and total assets were valued at 101.53 Cr as of March 2025.

As of 31st August, Lasa Supergenerics Ltd has a market capitalization of 34.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lasa Supergenerics reported net sales of 6.36 Cr. However, the company experienced a loss of 16.54 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where shareholder's funds amounted to 83.71 Cr and total assets were valued at 101.53 Cr.

Should I buy, sell or hold Lasa Supergenerics Ltd?

Are Lasa Supergenerics Ltd latest results good or bad?

Lasa Supergenerics Ltd's latest results are concerning, with a 100.33% decline in net sales and a widened net loss of ₹4.16 crores in Q4 FY26, indicating severe operational issues and a strong sell recommendation due to poor financial performance.

Lasa Supergenerics Ltd's latest results are quite concerning and can be classified as bad. In the fourth quarter of FY26, the company reported negative net sales of ₹0.13 crores, marking a staggering decline of 100.33% year-on-year. This indicates a severe operational collapse, as the company essentially recorded more returns or adjustments than actual sales during the quarter.<BR><BR>Additionally, the net loss for the quarter widened to ₹4.16 crores, a 63.14% increase from the previous quarter. The company's profitability metrics are alarming, with a Return on Equity (ROE) of just 0.32%, reflecting extremely weak capital efficiency. The overall financial performance shows a catastrophic decline, with a nine-month revenue for FY26 of only ₹5.13 crores, representing a 95.40% drop compared to the same period last year.<BR><BR>Market sentiment around the company is also negative, with the stock underperforming significantly against the broader Pharmaceuticals & Biotechnology sector. The company's Mojo Score, which assesses investment quality, stands at a dismal 9 out of 100, indicating a strong sell recommendation.<BR><BR>In summary, Lasa Supergenerics is facing a critical operational crisis, with deteriorating financials and a lack of institutional investor confidence, making the latest results decidedly bad.

When is the next results date for Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd will announce its results on 14 August 2026.

Lasa Supergenerics Ltd is scheduled to declare its results on 14 August 2026.

How has been the historical performance of Lasa Supergeneri?

Lasa Supergeneri has experienced significant fluctuations in financial performance, with net sales declining from a peak of 202.38 Cr in March 2021 to 142.45 Cr by March 2025, and operating profit turning negative in March 2023 before improving slightly to 6.27 Cr in March 2025. The company has also seen a decrease in reserves and earnings per share, with a negative profit before tax of -19.38 Cr in March 2025.

Answer:<BR>The historical performance of Lasa Supergeneri shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Lasa Supergeneri's net sales have varied, peaking at 202.38 Cr in March 2021 but declining to 142.45 Cr by March 2025, with a notable drop from 137.13 Cr in March 2022. Total operating income followed a similar trend, reflecting the same values as net sales. Raw material costs increased to 108.10 Cr in March 2025 from 79.28 Cr in March 2024, while total expenditure rose to 136.18 Cr in March 2025, indicating rising operational costs. Operating profit, which was positive at 47.22 Cr in March 2021, turned negative in March 2023 at -6.59 Cr and improved to 6.27 Cr by March 2025. Profit before tax remained negative, reaching -19.38 Cr in March 2025, with profit after tax also negative at -14.76 Cr. The company's equity capital remained stable at 50.10 Cr from March 2023 to March 2025, but reserves have significantly decreased from 107.96 Cr in March 2022 to 33.61 Cr in March 2025. The earnings per share have shown a downward trend, with a loss of -2.95 in March 2025 compared to a profit of 5.6 in March 2021. Cash flow from operating activities was positive at 2.00 Cr in March 2024, but the overall cash position has deteriorated, with closing cash and cash equivalents at 0.00 Cr in March 2024.

Who are the top shareholders of the Lasa Supergeneri?

The top shareholders of Lasa Supergeneri are primarily its promoters, with Omkar Pravin Herlekar holding 53.65% of the shares. Individual investors own 34.08%, and there are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Lasa Supergeneri primarily consist of its promoters. The largest individual shareholder is Omkar Pravin Herlekar, who holds 53.65% of the shares. Additionally, individual investors collectively own 34.08% of the company. There are no mutual funds or foreign institutional investors (FIIs) holding shares in Lasa Supergeneri at this time.

Is Lasa Supergeneri overvalued or undervalued?

As of April 5, 2023, Lasa Supergeneri is considered overvalued with a high PE ratio of 47.70, negative ROCE of -7.08%, and a significant year-to-date return of -48.37%, indicating it is priced for growth despite poor financial performance compared to peers like Aarti Industries.

As of 5 April 2023, Lasa Supergeneri has moved from a grade of does not qualify to risky. The company is currently overvalued based on its high PE ratio of 47.70, which is significantly above the industry average, and a negative ROCE of -7.08%. Additionally, the EV to EBITDA ratio stands at 11.50, indicating a premium valuation relative to its earnings potential.<BR><BR>In comparison to peers, Lasa Supergeneri's PEG ratio of 0.43 suggests that it is priced for growth, yet its financial performance does not support such a valuation. For instance, a peer like Aarti Industries has a PE ratio of 25.00, which highlights the disparity in valuation metrics. Furthermore, the company has underperformed the Sensex significantly, with a year-to-date return of -48.37% compared to the Sensex's 5.60%, reinforcing the notion that Lasa Supergeneri is overvalued in its current state.

What is the technical trend for Lasa Supergeneri?

As of April 25, 2025, Lasa Supergeneri exhibits a strong bearish trend supported by negative MACD, Bollinger Bands, and moving averages across multiple time frames.

As of 25 April 2025, the technical trend for Lasa Supergeneri has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both the weekly and monthly time frames, and the Bollinger Bands also indicate a bearish trend in both time frames. Daily moving averages confirm the bearish sentiment. The KST is bearish on both weekly and monthly charts, while the Dow Theory shows a mildly bearish stance on the weekly and monthly time frames. The OBV reflects a mildly bearish condition as well. Overall, the combination of these indicators suggests a strong bearish outlook for Lasa Supergeneri.

Has Lasa Supergeneri declared dividend?

Lasa Supergenerics Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 16, 2022. However, the company has faced significant negative returns across all periods, with total returns ranging from -34.27% to -81.34% over the past five years.

Lasa Supergenerics Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.20<BR>- Ex-date: 16 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -47.32%, with a dividend return of 0%, resulting in a total return of -47.32%.<BR><BR>Over the past year, the price return was -34.27%, with a dividend return of 0%, leading to a total return of -34.27%.<BR><BR>In the last 2 years, the price return was -40.94%, with a dividend return of 0%, resulting in a total return of -40.94%.<BR><BR>For the 3-year period, the price return was -66.99%, with a dividend return of 0.60%, leading to a total return of -66.39%.<BR><BR>In the 4-year period, the price return was -81.34%, with a dividend return of 0.48%, resulting in a total return of -80.86%.<BR><BR>Over the last 5 years, the price return was -67.68%, with a dividend return of 0.87%, leading to a total return of -66.81%.<BR><BR>Overall, Lasa Supergenerics Ltd has declared a dividend, but the company has experienced significant negative returns across all periods, indicating a challenging financial performance despite the dividend declaration.